City page
Oslo biotech and pharma directory
This page shows why the city matters, which categories are strongest there, and which compliance or quality markers are already visible in public evidence.
Where does this city read strongest?
Therapeutics (5), Diagnostics (2), and Cluster (1). Most visible records: Age Labs AS, Calluna Pharma AS, and ClexBio AS.
Which standards and public evidence are already visible?
GMP (1). Latest review: 24 April 2026. Review cycle: April 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Oslo.
By category
Oslo by category
Jump into a category page filtered to this country only.
Full list
Oslo biotech and pharma directory
9 city records currently match the active filter.
Current review cycle
Age Labs AS
OsloNorwayDiagnostics
Oslo molecular diagnostics startup developing DNA methylation and epigenetic biomarker tests for age-related diseases, with a lead candidate targeting early-stage rheumatoid arthritis diagnosis.
- Lead
- Andre LovestamChief Executive Officer
- Scale
- Molecular diagnostics development
Current review cycle
Calluna Pharma AS
OsloNorwayTherapeutics
Oslo clinical-stage antibody biotech targeting fibrosis and inflammation through the first-in-class anti-S100A4/S100A9 antibody CAL101, with Phase 1 completed in October 2024 and backing from Forbion.
- Lead
- Mark GaffneyChief Executive Officer
- Scale
- Clinical-stage antibody development
Current review cycle
ClexBio AS
OsloNorwayBiotech
Pre-clinical regenerative-medicine startup building vascularized, cell-synthesized extracellular-matrix implants via the CLEX hydrogel scaffold and VivoSet platform, with early applications in Type-1 diabetes, liver, and heart disease.
- Lead
- Armend G. HatiChief Executive Officer and Co-Founder
- Scale
- Pre-clinical tissue engineering
Current review cycle
Oncoinvent ASA
OsloNorwayTherapeutics
Oslo-listed clinical-stage radiopharmaceutical developer running Phase 2 trials of Radspherin, a radium-224 alpha-emitter microsphere for ovarian peritoneal metastases, following the October 2025 merger with BerGenBio.
- Lead
- Oystein SougChief Executive Officer
- Scale
- GMP clinical-trial-material production
Current review cycle
Oslo Cancer Cluster
OsloNorwayCluster
Norway's flagship oncology innovation cluster and Norwegian Centre of Expertise, co-locating approximately 100 cancer-focused biotech SMEs, Oslo University Hospital, and the Cancer Registry of Norway at the Ullern Innovation Park.
- Lead
- Ketil WiderbergGeneral Manager
- Scale
- Cluster coordination and incubator operations
Current review cycle
Thor Medical ASA
OsloNorwayTherapeutics
Oslo-listed radiopharmaceutical developer (formerly Nordic Nanovector) focused on alpha-emitter production (radium-224 and Pb-212) for next-generation cancer therapy, with pilot radionuclide production at Heroya.
- Lead
- Alf BjorsethChief Executive Officer
- Scale
- Pilot radiopharmaceutical production
Current review cycle
Zelluna ASA
OsloNorwayTherapeutics
Euronext Oslo-listed cell therapy company (formed February 2025 from the Ultimovacs and Zelluna Immunotherapy business combination) developing off-the-shelf TCR-NK cell therapies for solid tumors, with a lead MAGE-A4 program advancing toward IND.
- Lead
- Namir HassanChief Executive Officer
- Scale
- Clinical-stage cell therapy development
Current review cycle
Photocure
OsloNorwayDiagnostics
Oslo bladder-cancer diagnostics headquarters coordinating blue-light cystoscopy commercialization, clinical evidence, and market development.
- Lead
- Dan SchneiderPresident and Chief Executive Officer
- Scale
- Commercial diagnostics operations
Current review cycle
Nykode Therapeutics
OsloNorwayTherapeutics
Oslo clinical-stage immunotherapy company running its DNA-based platform, oncology programs, and partner-facing operations from the Oslo Science Park headquarters.
- Lead
- Michael EngsigChief Executive Officer
- Scale
- Drug Development
Related briefs
Briefs that mention Oslo
European mRNA & Immunotherapy Supply Chain 2026
Where the European mRNA, vaccine, and immunotherapy supply chain actually sits in 2026 — BioNTech, CureVac, IDT Biologika, AGC Biologics, BioSpring, Bachem, plus the Nordic vaccine layer — and how the pieces fit.
Open briefViral Vector CDMO Europe 2026: AAV, Adenovirus, Lentivirus
Where to manufacture viral vectors in Europe in 2026 — FinVector, Kuopio Center for Gene and Cell Therapy, 3PBIOVIAN, Fuse Vectors, IDT Biologika — and how the European viral vector CDMO layer is structured.
Open briefNordic Biotech Landscape 2026: Denmark, Sweden, Finland, Norway
A practical map of the Nordic biotech and pharma landscape in 2026 — 124 operators across Denmark, Sweden, Finland, and Norway, anchored by Novo Nordisk, Genmab, Lundbeck, AstraZeneca Gothenburg, Bavarian Nordic, Orion, and a dense Medicon Valley + Karolinska cluster layer.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.